Reanalysis of Study 329 Resulted in A New Discovery

Michael Lin Baum is an experienced lawyer who received his juris doctor from the University of California, Los Angeles. He is currently a managing partner of the Los Angeles Baum Hedlund Aristei & Goldman law firm. Attorney Michael Lin Baum represents individuals against major pharmaceuticals that have been harmed after taking drugs like Paxil. He and his law firm were instrumental in exposing the Paxil Study 329 study.

Paxil Study 329 was published by a group of accredited scientific researchers in 2001. The research essentially promoted Paxil prescription by health practitioners. However, subsequent speculation regarding the efficacy of the drug ensued. Multiple scientific researchers critiqued the research’s conclusion but could not successfully cause retraction of the publication.

While conducting the Paxil litigation, Baum Hedlund observed multiple controversies regarding the pharmaceutical efficacy of Paxil and subsequently deposed the lead author of Study 329, who finally admitted that he only went through an abridged version of the statistical data rather than scrutinizing the raw data to confirm the validity of the statistical result.

Some researchers reanalyzed the raw data used in Study 329 in a new project called RIAT. Restoring Invisible and Abandoned Trials (RIAT) is an initiative geared towards improving the integrity of scientific publications on drug efficacy and safety. Reanalysis of raw data by the researchers found that the conclusion of Study 329 is wholly erroneous and that Paxil is ineffective and causes suicidal behavior in young people.